Cargando…
A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Between 2000 and 2005 several studies revealed that morphine is more potent and exhibits fewer side effects in beta-arrestin 2 knockout mice. These findings spurred efforts to develop opioids that signal primarily via G protein activation and do not, or only very weakly, recruit beta-arrestin. Devel...
Autores principales: | Mores, Kendall L., Cummins, Benjamin R., Cassell, Robert J., van Rijn, Richard M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478756/ https://www.ncbi.nlm.nih.gov/pubmed/31057409 http://dx.doi.org/10.3389/fphar.2019.00407 |
Ejemplares similares
-
Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities
por: Meqbil, Yazan J., et al.
Publicado: (2021) -
G protein‐biased kratom‐alkaloids and synthetic carfentanil‐amide opioids as potential treatments for alcohol use disorder
por: Gutridge, Anna M., et al.
Publicado: (2020) -
The Meta-Position of Phe(4) in Leu-Enkephalin Regulates Potency, Selectivity, Functional Activity, and Signaling Bias at the Delta and Mu Opioid Receptors
por: Cassell, Robert J., et al.
Publicado: (2019) -
Therapeutic Potential of Kappa Opioid Agonists
por: Beck, Tyler C., et al.
Publicado: (2019) -
Desmetramadol Is Identified as a G-Protein Biased µ Opioid Receptor Agonist
por: Zebala, John A., et al.
Publicado: (2020)